blank
blank

ERDERA Clinical Trial Call – Guidelines for Applicants

1:1
These guidelines explain the eligibility rules, submission process and Expression of Interest requirements for the ERDERA Clinical Trial Call.

This document sets out the aim, eligibility criteria, application process, and application instructions for the ERDERA Clinical Trial Call(ECTC).  It also explains the sections required for the Expression of Interest, including project data, project description, the coordinating investigator and sponsor, partners, budget, notes, declarations, submission and data protection.

Acces this publication
blank

publication

ERDERA clinical trial call

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

You might also be interested in

webinar series ERDERA

Introductory webinar: Situating ethics in the research continuum

July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
State of the art rare disease country reports ERDERA

State of the art 2026 rare disease country report: Poland

This 2026 country report outlines the policy, research, care and support landscape for rare diseases in Poland.
NMG workshop 2026

ERDERA National Mirror Groups workshop: Creating, evolving and utilising national registries to advance rare disease research

Held in Riga on 9–10 June, the workshop brought National Mirror Group experts, researchers, clinicians and policymakers together to exchange practical lessons on how national rare disease registries can better support research and alignment across countries.
2

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.

ERDERA's

search form